Saturday, May 10, 2008
CELLCENTRIC LIMITED
is pioneering novel approaches to generate therapeutics, principally
for the treatment of degenerative disorders and cancer. The products
are based on the world-leading research led by Professor Azim Surani FRS at the University of Cambridge. The technology and ensuing intellectual property will underpin a strong product pipeline.
The company will focus on those factors and drugs modulating their
activity that will induce tissue repair and replacement for the
treatment of diseases such as diabetes, CNS and blood-related
disorders. They are also expected to have utility in the treatment
of other diseases, such as cancer.
